Transcutaneous Sensors for the Detection of Cancer-Related Lymphedema, Project Limb Rescue Study
Launched by OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER · Mar 5, 2024
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called the Limb Rescue Study, is examining how effective new skin sensors are at detecting lymphedema, which is long-term swelling in the arms related to cancer. Lymphedema can be painful and uncomfortable, and catching it early is important for better treatment outcomes. The sensors used in this study, which stick to the skin, work by measuring changes in blood volume and how tissue reacts to small electrical currents. This could help patients monitor their own condition at home, making it easier to identify swelling early.
To participate in the study, you may be eligible if you are between the ages of 65 and 74 and fit into one of two groups: either you are healthy or you have lymphedema due to previous cancer treatments that involved surgery or radiation. If you have swelling in one arm that requires treatment, this study may be for you. Participants will be monitored to see how well these new sensors can detect lymphedema compared to standard methods. Remember, this study is actively recruiting participants, so if you think you might qualify, it could be a great opportunity to help advance care for lymphedema.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • COHORT A: Healthy participants
- • COHORT B: Participants with pre-existing lymphedema
- • COHORT B: A history of cancer therapy with surgery or radiation involving the axillary basin
- • COHORT B: Unilateral upper extremity swelling that requires compression or pneumatic therapy or a \>= 2-centimeter difference in contralateral arm circumference
- Exclusion Criteria:
- • Patients with active malignancy or ongoing cancer therapy will be excluded, though breast cancer patients currently on endocrine monotherapy will be included
About Ohio State University Comprehensive Cancer Center
The Ohio State University Comprehensive Cancer Center (OSUCCC) is a leading institution dedicated to advancing cancer research, treatment, and education. As a National Cancer Institute-designated comprehensive cancer center, OSUCCC integrates cutting-edge research with clinical practice to develop innovative therapies and improve patient outcomes. With a collaborative approach that unites scientists and clinicians, OSUCCC focuses on personalized medicine, cancer prevention, and community outreach, striving to enhance the understanding of cancer biology and provide hope to patients through groundbreaking clinical trials and comprehensive care programs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Columbus, Ohio, United States
Patients applied
Trial Officials
Carlo M Contreras, MD
Principal Investigator
Ohio State University Comprehensive Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported